← Back to headlines
Moderna Stock Soars 179% on Melanoma Therapy Candidate Success
Moderna's stock has surged by 179% following positive developments regarding its melanoma therapy candidate, which is seen as rewriting the company's growth story.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
